NanoGhost Overview

  • Founded
  • 2019
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $5M
Latest Deal Amount
  • Investors
  • 1

NanoGhost General Information


Developer of a drug-delivery technology intended to shrink the deadliest forms of cancer by precisely targeting tumors. The company's technology aids in reducing tumor size in small lung carcinoma, prostate and pancreatic cancer tumors, by as much as 85%, enabling patients suffering from cancer to reduce the pain of radiology treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
  • Haifa
  • Israel
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoGhost Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 23-Dec-2019 $5M 000 000.00 Completed Startup
To view NanoGhost’s complete valuation and funding history, request access »

NanoGhost Executive Team (2)

Name Title Board Seat Contact Info
Marcelle Machluf Co-Founder
Yonatan Malca Co-Founder & Chief Executive Officer
To view NanoGhost’s complete executive team members history, request access »

NanoGhost Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
aMoon Fund Venture Capital Minority 000 0000 000000 0
To view NanoGhost’s complete investors history, request access »